Second Opinion

SECOND OPINION: LATEST PHRMA AD CAMPAIGN DEFENDS PATENT ABUSE “STATUS QUO”

Jun 26, 2024

Big Pharma Advertising Blitz Seeks to Protect Anti-Competitive Tactics That Read More

SECOND OPINION: BIG PHARMA’S OUT-OF-POCKET PLANS ON BRAND NAME INHALERS MAY BE DESIGNED TO FURTHER UNDERMINE COMPETITION

Apr 8, 2024

Big Pharma’s Announcements Designed to Deflect from Criticism and Scrutiny Read More

SECOND OPINION: DEBUNKING BIG PHARMA’S BOGUS INNOVATION RHETORIC

Sep 19, 2023

Brand Name Drug Companies Claim Lowering Rx Prices Will Undercut R&D — Read More

SECOND OPINION: BIG PHARMA EXEC BOOED AS HE DISMISSES AFFORDABILITY CONCERNS ON HIGH PRICED TREATMENTS AS “LUDICROUS”

Dec 9, 2022

Regeneron Co-Founder Says, “Forget About That” When Pressed on How Read More

SECOND OPINION: AVIK ROY DEBUNKS BIG PHARMA’S INNOVATION RHETORIC

Sep 1, 2022

FREOPP President Explains Pharmaceutical Industry Arguments Are “Factually Read More

SECOND OPINION: PHRMA’S LAST-DITCH ATTEMPT TO DERAIL SOLUTIONS TO LOWER DRUG PRICES REHASHES DEBUNKED ARGUMENTS

Aug 5, 2022

Pharmaceutical Industry Attempts to Intimidate Lawmakers and Keep Prices High Read More

SECOND OPINION: BIG PHARMA’S PRICE HIKES HAVE LONG OUTPACED INFLATION

Jul 11, 2022

PhRMA Ads Falsely Claim the Industry’s Egregious Pricing Practices Don’t Read More

SECOND OPINION: PHRMA REDUXES DEBUNKED BLAME GAME RHETORIC IN NEW AD CAMPAIGN

Jun 17, 2022

Big Pharma Trots Out Tired, Dishonest Arguments Designed to Evade Read More

SECOND OPINION: PHRMA STUDY REHASHES DEBUNKED SUPPLY CHAIN BLAME GAMES

Feb 3, 2022

Big Pharma Sidesteps Industry’s Own Price Hikes and Egregious Practices in Read More